Page 65 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Leading US hospitals team up to promote COVID-19 vaccination
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Epizyme s EZH2 blocker boosts immuno-oncology response in prostate cancer models
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
CONTENT: Press Release
HOUSTON, April 14, 2021 /3BL Media/ - DiversityFirstTM is recognizing the 2021 Top HR Professionals at the 17th Annual National Diversity and Leadership Conference virtually on April 21-22 and April 28-29. Award winners have been selected from organizations across the country and represent various industries such as healthcare, technology, and entertainment.
“As diversity, equity, and inclusion are finally being seen and acknowledged as serious, pressing matters of discussion, we are delighted to honor and recognize those who have been tirelessly championing belonging and allyship - even before the topic was on the forefront of Americans’ minds. We thank you, our top HR Professionals, for your work and commitment, and we look forward to witnessing all that you’ll accomplish, all the leaders that you’ll develop, and the impact you’ll leave behind in the DEI sphere.” says National Diversity Council founder Dennis Kennedy.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Affimed N.V.April 15, 2021 GMT
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL
AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses
AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021
AFM24 combination with NK cells: IND application cleared by the FDA for the combination of AFM24 with NKGen Biotech’s SNK-01 NK autologous cell therapy
vimarsana © 2020. All Rights Reserved.